Compare Charter Communications Inc (CHTR) vs Gilead Sciences, Inc. (GILD) Price & Performance

Charter Communications (CHTR) trades at $152.57, down 3.09% on the day, with a bullish technical signal from moving averages but mixed oscillators. The stock shows low valuation multiples with a P/E of 3.97 and P/S of 0.36, supported by a 9.05% net income margin and strong operating cash flow of $16.08B in 2025. Recent Q2 2026 earnings beat expectations with EPS of $10.66 versus $9.98 estimated, though revenue declined 1.7% year-over-year. News highlights debt refinancing activities and competitive pressures in broadband.

The outlook remains cautious due to subscriber losses and fiber competition, but the extreme valuation discount and aggressive buybacks offer potential upside. Risks include high debt leverage at $93.21B long-term and persistent industry headwinds. Analyst consensus is mixed with a $166.18 price target, suggesting 9% upside from current levels.

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.